Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02469259 · ClinicalTrials.gov registry record · Early Phase 1
The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD
A Early Phase 1 study of Alcoholism and Stress Disorders, Post-Traumatic, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT02469259 is a Early Phase 1 study of Alcoholism and Stress Disorders, Post-Traumatic that has completed, run by University of California, San Francisco. The registered enrollment target is 88 participants, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02469259, a Early Phase 1 study of Alcoholism and Stress Disorders, Post-Traumatic, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the effects of oxytocin on alcohol-related behaviors, social abilities, and physiological startle responses in healthy individuals and patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) using a randomized, placebo-controlled, dose-tiered, between-subject study design. Specifically, the investigators will determine if intranasal administration of a single dose of the pro-social neuropeptide oxytocin decreases alcohol-related approach bias and cravings, enhances social abilities, and decreases physiological hyperactivity. The investigators will also determine the optimal dose to achieve these effects and will explore psychosocial predictors of responses to oxytocin. The proposed work has the potential to yield a novel pharmacological treatment for AUD and PTSD, both leading causes of disability in the US Military for which currently available treatments are inadequate.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Oxytocin
Study Locations (1)
California
- San Francisco Veterans Affairs Medical Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2016-02 |
| Est. Completion | 2018-02-28 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02469259
The ClinicalTrials.gov registry entry for NCT02469259 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 65 other Alcoholism trials with a reported enrollment target (76% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02469259 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02469259 about?
NCT02469259 is a clinical study titled "The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD". This study will investigate the effects of oxytocin on alcohol-related behaviors, social abilities, and physiological startle responses in healthy individuals and patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) using a randomized, placebo-controlled, dose-tiered, be...
What is the current status of trial NCT02469259?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 88 participants. The study started on 2016-02. Estimated completion is 2018-02-28.
What conditions does trial NCT02469259 study?
This clinical trial studies the following conditions: Alcoholism, Stress Disorders, Post-Traumatic.
What interventions are being tested in trial NCT02469259?
The interventions under investigation include: Placebo (OTHER), Oxytocin (DRUG).
Who is sponsoring clinical trial NCT02469259?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02469259 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcoholism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Alcohol Responses (BAR) Study
ACTIVE NOT RECRUITING · Early Phase 1
-
The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion
COMPLETED · Early Phase 1
-
Naltrexone in AUD Reward Drinkers
RECRUITING · Phase 4
-
Characterization Imaging Instruments in Alcoholics and Non-Alcoholics
RECRUITING
-
Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder
RECRUITING · NA
-
Alcohol and the Social Brain: an Alcohol-Administration Hyperscanning Study
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.